Bristol Myers Squibb (BMS; NYSE: BMY) has participated in an oversubscribed Series B extension round for NeoPhore, a UK-based immuno-oncology company. The funds will be utilized by NeoPhore to advance its pre-clinical studies, with the goal of delivering a small-molecule candidate by 2025. The specific amount invested by BMS was not disclosed.
NeoPhore specializes in first-in-class inhibitors that target novel proteins within the DNA mismatch repair (MMR) pathway. Their approach aims to stimulate neoantigen creation and enhance the sensitivity of cancer cells to immunotherapy.- Flcube.com
